Mr. Davies was appointed Vice President, Instruments, Reagents, and Consumable Manufacturing in February, 2019 with responsibility for Luminex’s flow cytometry, microcapillary flow cytometry, imaging, and real-time PCR platforms. Mr. Davies joined Luminex in 1996 as one of the company’s earliest hires, and made foundational contributions to the proof of concept, product development, and commercialization readiness of Luminex’s xMAP® Technology. Since this time, he has held a range of Manufacturing Operations leadership roles in which he has architected teams, programs, processes, and driven continuous improvement. Mr. Davies holds a B.S. degree in Microbiology from The University of Texas at Arlington.
Ryan Snellings joined Luminex in August 2018 as the Vice President of Global Customer Operations. Ryan supports both operations and sales functions across the globe to ensure a positive customer experience. Prior to Luminex, Ryan was responsible for Fenwal, Inc.’s Europe, Middle East, and Africa operations before Fenwal, Inc. was acquired by Fresenius Kabi in 2013. With the acquisition, Ryan was promoted to Vice President of Field Service and Support at Fresenius Kabi. Over the last few years, Ryan has held international leadership roles with increasing responsibility for both North America and Europe. Ryan is a graduate from Florida State University with an MBA from Keller Graduate School of Management.
Stephen L. Eck, MD, PhD, age 61, joined the board of directors in March 2016. Since 2011 he has served as the Vice President, Oncology Medical Sciences of Astellas Pharma Global Development, a global pharmaceutical company. He is responsible for the design and conduct of domestic and international oncology clinical studies, which include the use of molecular testing for disease diagnosis and to monitor drug efficacy and safety.
From 2007 to 2011, Dr. Eck served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly, a global pharmaceutical company. There, he was responsible for the clinical pharmacology components of drug development, including both early phase clinical studies and late stage drug development studies. He was responsible for the Diagnostic and Experimental Medicines and laboratory for Experimental Medicine departments which designed, built and deployed novel clinical test platforms to be used in clinical studies. Before his tenure at Eli Lily, Dr. Eck led drug development teams at Pfizer from 2002 to 2007, including the Molecular Profiling Group and the Translational Medicine organization.
Prior to joining the pharmaceutic industry, Dr. Eck was a member of the faculty of the University of Pennsylvania School of Medicine, where he focused on Hematology and Oncology. He is a Fellow of the American Association for the Advancement of Science. He also serves on the Scientific Advisory Board of the ACGT Foundation, the Board of Trustees of the Keck Graduate Institute, the Board of Directors of the Central Pennsylvania Clinic, and on the Board of Directors of the Personalized Medicine Coalition. Dr. Eck holds a B.S. in Chemistry from Kalamazoo College, a Ph.D. in Chemistry from Harvard University and a M.D. in Medicine from the University of Mississippi.
Thomas W. Erickson, age 61. Mr. Erickson has served as a member of the board of directors since May 2004. Mr. Erickson served as our Interim President and Chief Executive Officer from September 2002 until our hiring of Mr. Balthrop in May 2004. He is currently chairman of the board of Inmar, Inc., a reverse logistics and revenue recovery company. Previously, he served as a Senior Advisor to New Mountain Capital, LLC, a private equity firm, chairman and interim president of National Medical Health Card Systems, Inc., a pharmacy benefits manager, chairman of the board of PATHCare, Inc., an operator of long term care facilities, chairman of the board of TransHealthcare, Inc., a health care services company, chairman and interim president and chief executive officer of LifeCare Holdings, Inc., an operator of long-term acute care hospitals, and interim president and chief executive officer and director of Omega Healthcare Investors, Inc., a healthcare focused real estate investment trust. Mr. Erickson was also co-founder, president and chief executive officer of CareSelect Group, Inc., a physician practice management company. Earlier in his career, he held several management positions at American Hospital Supply Corporation. Mr. Erickson currently serves on the board of directors of American Renal Associates, a national provider of kidney dialysis services. Mr. Erickson holds a Bachelors degree from University of Iowa and an M.B.A. from Southern Methodist University.
Mr. Erickson brings to the board of directors extensive experience managing and growing healthcare industry companies, as well as significant general experience serving in leadership roles on boards and board committees of other public companies. Through his experience serving as Luminex’s Interim President and Chief Executive Officer from September 2002 until May 2004, Mr. Erickson offers to the board detailed insight into the Company’s business and management considerations. Through his substantial experience in the healthcare industry, in particular healthcare services and delivery, Mr. Erickson offers valuable insight on Luminex and its product offerings from the perspective of healthcare providers.
Jim D. Kever, age 59. Mr. Kever has served as a member of the board of directors since December 1996. He has been a member in Voyent since August 2001. Mr. Kever served as co-chief executive officer of the transaction services division of WebMD from June 2000 to March 2001. From March 1999 through May 2000, Mr. Kever served as chief executive officer of the transaction services division of Quintiles. From August 1995 through March 1999, Mr. Kever was the president and co-chief executive officer of Envoy. Mr. Kever serves on the boards of directors of 3D Systems Corporation (“3D Systems”), a provider of 3-D printing, rapid prototyping and manufacturing solutions, and Tyson Foods, Inc., a food production company (“Tyson”). Within the past five years, Mr. Kever has served on the board of directors of ACI Worldwide, Inc., a global provider of electronic payments solutions for financial institutions. Mr. Kever holds a B.S. in business administration from the University of Arkansas and a J.D. from the Vanderbilt University School of Law.
Mr. Kever brings to the board of directors extensive experience managing and growing healthcare industry companies. Mr. Kever brings experience in serving on public and private boards. Mr. Kever, through his more recent investment experiences with Voyent, also brings depth of knowledge in managing and growing companies and in capital market considerations. Mr. Kever also brings continuity to the board of directors, given his service on the board since Luminex’s earliest years of operation.
Kevin M. McNamara, age 56. Mr. McNamara has served as a member of the board of directors since May 2003. In addition, he provided financial and strategic consulting services to the Company from October 2001 through December 2002. Mr. McNamara served as executive vice president, chief financial officer and treasurer of HealthSpring, Inc., a managed care company, from April 2005 through May 2009. Mr. McNamara also served as non-executive chairman from April 2005 through January 2006 of MedAvant Healthcare Solutions (f/k/a ProxyMed, Inc.), a provider of automated healthcare business and cost containment solutions for financial, administrative and clinical transactions in the healthcare payments marketplace, and served as interim chief executive officer and as a director of ProxyMed, Inc. from December 2004 through June 2005. Mr. McNamara previously served as chief financial officer of HCCA International, Inc., a healthcare management and recruitment company from October 2002 to April 2005. Mr. McNamara currently serves on the board of directors of Tyson Foods, Inc., a food production company. Within the past five years, Mr. McNamara has served on the board of directors of COMSYS IT Partners, Inc. (f/k/a Personnel Group of America, Inc.), an information technology staffing and solutions provider. Mr. McNamara is a Certified Public Accountant (inactive) and holds a B.S. in Accounting from Virginia Commonwealth University and an M.B.A. from the University of Richmond.
Mr. McNamara brings to the board of directors extensive financial expertise, experience managing and growing healthcare industry companies, as well as significant general experience serving on boards and board committees of other public companies. Mr. McNamara’s experience overseeing risk assessment, accounting and financial reporting for public and other healthcare companies provides equally valuable experience in his role as chair of our Audit Committee. Mr. McNamara also has experience overseeing public and private capital markets and mergers and acquisitions transactions.
Edward A. Ogunro, Ph.D., age 59. Dr. Ogunro has served as a member of our board of directors since May 2009. Dr. Ogunro served as senior vice president, R&D and medical affairs and chief scientific officer at Hospira Inc., a global specialty pharmaceutical and medication delivery company, from April 2004 until December 2007. Prior to Abbott’s spin-off of Hospira in 2004, Dr. Ogunro served in a number of leadership positions for over 20 years with Abbott, primarily in Abbott’s Diagnostics Division, and most recently served as corporate vice president, R&D, medical and regulatory affairs in Abbott’s Hospital Products Division. He held numerous other positions with Abbott, including program director for AxSym, one of the most successful analyzers in the diagnostic industry, and divisional vice president for Abbott’s Immunodiagnostics and Chemistry R&D Organization. Dr. Ogunro served on the board of directors of Applied NeuroSolutions, Inc., a company focused on the development of an integrated portfolio of products for the treatment and diagnosis of Alzheimer’s disease. Previously, Dr. Ogunro pursued postdoctoral studies and served as an assistant professor at Northwestern University Medical School in Chicago from 1977 to 1982. Dr. Ogunro holds a B.S. in Physiology and Biochemistry from Reading University and a Ph.D. in Biochemistry from London University.
Dr. Ogunro brings to the board of directors significant directly relevant technical and operational industry experience in the diagnostics and medical device industry. Dr. Ogunro has substantial experience in managing complex research and development initiatives for large, evolving portfolios of diagnostic and medical device products, and in securing and maintaining regulatory clearance for such products both domestically and internationally. Dr. Ogunro’s technical background and direct experience with project management is of particular relevance in his role on the Strategy and Development Committee and in guiding Luminex in its research and development investments on new products and markets.
Mr. Samet joined our Board in December, 2018. Mr. Samet has served as Chief Executive Officer of MedStar Health, Inc., a non-profit healthcare delivery system, since 2008. He previously served as that organization’s President from 2003 and as Chief Operating Officer from 1998. From 1990 to 2000, Mr. Samet served as President of MedStar Washington Hospital Center. From the mid-1980s to 1990, he held a variety of leadership positions with the Medlantic Healthcare Group. Mr. Samet has also served as a director of Catalyst Health Solutions, Inc., Cogentix Medical, Inc., and Evolent Health, Inc. Mr. Samet received a bachelor’s degree in business administration from Old Dominion University and a master’s degree in health services administration from the University of Michigan.
Mr. Samet brings to the Board of Directors extensive experience managing and growing healthcare industry companies, as well as significant general experience serving in leadership roles on boards and board committees of other public companies. He also brings financial expertise, a diverse set of capabilities in leading the operational aspects of a large and complex organization, and experience managing issues representative of those faced by the Company’s customers.